ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/VEGF-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/VEGF-inhibitor
8
trial(s) found.
NCT04938817
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98) (
3475-B98
)
anti-PD-1 monoclonal antibody
+ VEGF inhibitor
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital (COMPLETED)
WA
6009 - Nedlands - Hollywood Private Hospital
NCT04305054
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B (
3475-02B
)
anti-PD-1 monoclonal antibody
+ VEGF inhibitor
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4215 - Southport - Tasman Oncology (COMPLETED)
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ KIT/PDGFR/RET/VEGFR inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
+ VEGF inhibitor
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (SUSPENDED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT02861573
Advanced
Phase 1 / Phase 2
Recruiting
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (
KEYNOTE-365
)
anti-PD-1 monoclonal antibody
+ VEGF inhibitor
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12618001825246
Advanced
Phase 2 / Phase 3
Recruiting
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma (
2014-000259-99
)
Carboplatin
Cyclophosphamide
Docetaxel
Etoposide
Gemcitabine
Ifosfamide
Irinotecan
Lenvatinib
Temozolomide
Topotecan
VEGF inhibitor
alkylating agent
antimetabolite
cancer therapy
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
+ VEGF inhibitor
Ewing sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06036836
Advanced
Phase 2
Active not recruiting
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010) (
4280A-010
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
+ VEGF inhibitor
Cutaneous squamous cell carcinoma
Endometrial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05545969
Curative
Phase 2
Withdrawn
A Multicentre, Open Label, Phase II Study to Determine the Response to Neoadjuvant Pembrolizumab and Lenvatinib Followed by Adjuvant Treatment With Pembrolizumab and Lenvatinib in Mucosal Melanoma (
Neo-PeLeMM
)
VEGF inhibitor
anti-PD-1 monoclonal antibody
Mucosal melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Enrolling by invitation (1)
Active not recruiting (1)
Withdrawn (1)
Recruitment Country and State
NSW (8)
QLD (6)
VIC (5)
WA (5)
NZ (3)
SA (3)
Phase
Phase 1 / Phase 2 (3)
Phase 2 (2)
Phase 2 / Phase 3 (1)
Phase 3 (2)
Trial Type
Advanced (7)
Curative (1)
Cancer Therapy Class
VEGF
100%
PD-1
88%
PD-1/PD-L1
88%
LAG3
63%
TIGIT
38%
PARP
38%
CTLA4
25%
ILT4
13%
ERBB2
13%
HPK1
13%
KIT
13%
OX40
13%
PDGFR
13%
RET
13%
VEGFR
13%
VEGFR1
13%
VEGFR2
13%
VEGFR3
13%
AR
13%
CYP17A1
13%
HIF2a
13%
androgen axis
13%
Facility
3168 - Clayton - Monash Medical Centre (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
4215 - Southport - Tasman Oncology (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2109 - North Ryde - Macquarie University Hospital (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
4032 - Chermside - The Prince Charles Hospital (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2060 - North Sydney - Mater Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
Cancer Type
Cancer
Solid tumour
Melanoma
Carcinoma
Lung cancer
Neuroendocrine carcinoma
Respiratory tract cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Thoracic cancer
Haematological malignancy
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Urogenital cancer
Bone cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Sarcoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Gynaecological cancer
Non-melanoma skin cancer
Skin cancer
Mucosal melanoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy